Mirtazapine for Depression in Patients With Human Immunodeficiency Virus
Authors:
- Andrew J. ElliottAEAndrew J. Elliott
- Peter P. Roy-ByrnePRPeter P. Roy-Byrne
- 1 April 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 20 (2) , 265-267
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Antidepressant Efficacy in HIV-Seropositive Outpatients With Major Depressive DisorderThe Journal of Clinical Psychiatry, 1999
- Weight Loss as a Predictor of Survival and Disease Progression in HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 1998
- Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDSGeneral Hospital Psychiatry, 1997
- Antagonism of selective serotonin reuptake inhibitor-induced nausea by mirtazapineInternational Clinical Psychopharmacology, 1997
- Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United StatesArchives of General Psychiatry, 1994
- Psychopathology in human immunodeficiency virus infection: Lifetime and current assessmentComprehensive Psychiatry, 1993
- HIV wasting syndrome in the United StatesAIDS, 1993
- General Versus Systematic Inquiry about Emergent Clinical Events with SAFTEEJournal of Clinical Psychopharmacology, 1992
- Conceptualization and Rationale for Consensus Definitions of Terms in Major Depressive DisorderArchives of General Psychiatry, 1991
- Lifetime Prevalence of Specific Psychiatric Disorders in Three SitesArchives of General Psychiatry, 1984